AR and cancer: This suggested that at a point in the evolutionary timescale of cancer progression, the CA63_3 clone acquired a genomic event that amplified AR and at death was the most abundant clone in the bone and lymph node metastases whilst the liver metastases and porta hepatic lymph nodes were populated by the non-amplified clone shared with CA63_2 (Fig. 5e).